Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.

• Main Authors: Marco Capece, Lorenzo Spirito, Roberto La Rocca, Luigi Napolitano, Roberto Buonopane, Sergio Di Meo, Maurizio Sodo, Umberto Bracale, Nicola Longo, Alessandro Palmieri, Ferdinando Fusco, Paolo Verze, Gianluigi Califano, Felice Crocetto, Ciro Imbimbo, Vincenzo Mirone, Vittorio Imperatore, Massimiliano Creta
• Format: Article
• Language: English
• Published: PAGEPress Publications 2020-04-01
• Series: Archivio Italiano di Urologia e Andrologia
• Subjects: Bladder cancer; Hexaminolevulinate; TURB; PDD; Fluorescence cystoscopy
• Online Access: https://www.pagepressjournals.org/index.php/aiua/article/view/8314

Background: Bladder cancer is the eleventh most commonly diagnosed cancer worldwide. The recurrence rate of this cancer can be very high, up to 45%. Photodynamic diagnosis (PDD) is more sensitive than standard procedures for the detection of malignant tumours. The aim of the study was to evaluate oncological outcomes in white light TURB (WL-TURB) and hexaminolevuninate blue light TURB (Hal-TURB). Patients and methods: This was a retrospective longitudinal single-center study. In the period between January 2016 and October 2016 WL-TURB was the only therapeutic option available. From November 2016 until April 2017 all TURBs were fluorescence-guided (Hal-TURB). Kaplan-Meier curves have been used to estimate recurrence free survival rates. Results: One hundred and eleven patients underwent Hal- TURB and 137 underwent WL-TURB. Recurrence rate after 12 months was 19.8% (22 out of 111 patients) and 37.2% (51 out of 137 patients) in HAL-group and WL-group respectively (p < 0.01). The recurrence-free period was longer in HAL-group rather than WL-group (8.9 months vs 7.3 months, p < 0.05). Moreover, the recurrence rate during the first 6 months was 3.7% in patients who underwent HAL-TURB and 16% in those who received WL-TURB (p < 0.01). Conclusion: The results of the study show that recurrence-free survival was longer in patients undergoing HAL-TURB compared to the patients who received standard WL-TURB.